RS60581B1 - Dekarboksilaza glutamske kiseline (gad) za upotrebu u lečenju autoimune bolesti - Google Patents

Dekarboksilaza glutamske kiseline (gad) za upotrebu u lečenju autoimune bolesti

Info

Publication number
RS60581B1
RS60581B1 RS20200789A RSP20200789A RS60581B1 RS 60581 B1 RS60581 B1 RS 60581B1 RS 20200789 A RS20200789 A RS 20200789A RS P20200789 A RSP20200789 A RS P20200789A RS 60581 B1 RS60581 B1 RS 60581B1
Authority
RS
Serbia
Prior art keywords
gad
diabetes
glutamic acid
cells
antigen
Prior art date
Application number
RS20200789A
Other languages
English (en)
Serbian (sr)
Inventor
Anders Essen-Möller
Johnny Ludvigsson
Original Assignee
Diamyd Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diamyd Medical Ab filed Critical Diamyd Medical Ab
Publication of RS60581B1 publication Critical patent/RS60581B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01005—Acetolactate decarboxylase (4.1.1.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RS20200789A 2014-06-04 2015-06-04 Dekarboksilaza glutamske kiseline (gad) za upotrebu u lečenju autoimune bolesti RS60581B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE1450678 2014-06-04
SE1451315 2014-11-04
PCT/SE2015/050651 WO2015187087A2 (en) 2014-06-04 2015-06-04 Novel combinations for antigen based therapy
EP15802815.9A EP3151853B1 (en) 2014-06-04 2015-06-04 Glutamic acid decarboxylase (gad) for use in the treatment of an autoimmune disease

Publications (1)

Publication Number Publication Date
RS60581B1 true RS60581B1 (sr) 2020-08-31

Family

ID=54767532

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200789A RS60581B1 (sr) 2014-06-04 2015-06-04 Dekarboksilaza glutamske kiseline (gad) za upotrebu u lečenju autoimune bolesti

Country Status (20)

Country Link
US (3) US20170196949A1 (enExample)
EP (2) EP3760224A3 (enExample)
JP (2) JP6686007B2 (enExample)
CN (2) CN114504639A (enExample)
AU (3) AU2015268960B2 (enExample)
CA (2) CA2950893C (enExample)
CY (1) CY1123160T1 (enExample)
DK (1) DK3151853T3 (enExample)
ES (1) ES2807787T3 (enExample)
HU (1) HUE051151T2 (enExample)
IL (3) IL300130B2 (enExample)
LT (1) LT3151853T (enExample)
PL (1) PL3151853T3 (enExample)
PT (1) PT3151853T (enExample)
RS (1) RS60581B1 (enExample)
RU (1) RU2702632C2 (enExample)
SI (1) SI3151853T1 (enExample)
SM (1) SMT202000384T1 (enExample)
WO (1) WO2015187087A2 (enExample)
ZA (1) ZA202204777B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
WO2019050458A1 (en) 2017-09-08 2019-03-14 Diamyd Medical Ab IMPROVED IMMUNOTHERAPY
KR102781844B1 (ko) 2017-09-08 2025-03-14 다이아미드 메디칼 에이비 당뇨병 치료 및 예방에서 유전자형 분류
US20200360496A1 (en) * 2018-02-05 2020-11-19 Diamyd Medical Ab Novel composition and use thereof
US11752156B2 (en) 2018-03-07 2023-09-12 Athenex HK Innovative Limited Compositions and methods for treating hyperproliferative skin disorders
US10500217B2 (en) 2018-04-30 2019-12-10 Leslie Ray Matthews, M.D., Llc Vitamin D3, heat shock proteins, and glutathione for the treatment of chronic inflammation and chronic diseases
WO2020210798A1 (en) * 2019-04-12 2020-10-15 Loma Linda University Methods for treatment of niemann-pick disease type c
WO2022104388A2 (en) * 2020-11-16 2022-05-19 W. L. Gore & Associates, Inc. Formulations, methods, and pre-filled injection devices without fatty acid particles
US20240245762A1 (en) * 2021-01-13 2024-07-25 University Of Maryland, College Park Methods and platforms for promoting antigen-specific tolerance in the treatment of type 1 diabetes and graft rejection and compositions relating thereto
US20240277768A1 (en) * 2021-06-17 2024-08-22 Tihamer Orban Individualized Cell Therapy Using Patient-Derived Antigen-Specific Regulatory T Cells
WO2023066881A1 (en) * 2021-10-18 2023-04-27 Astrazeneca Ab Inhibition of map3k15 for treating and preventing diabetes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
KR19990063648A (ko) * 1995-09-21 1999-07-26 프레드한 아룬디프 에스 글루타민산 데카복실라제에 대한 항체와 폴리(에틸렌 글리콜)공액물을 섬세포에 제공하는 방법
SE9503379D0 (sv) * 1995-09-29 1995-09-29 Synectics Medical Ab A modified GAD, a method for producing a modified GAD, a method for supplying a modified GAD, a peptide and the use of an ordinary and/or a modified GAD
US6884785B2 (en) 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes
EP2322185A3 (en) * 2001-11-21 2011-08-10 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
US20050152914A1 (en) * 2003-06-13 2005-07-14 Diamyd, Inc. Formulation of antigen
CA2554978A1 (en) * 2004-02-04 2005-08-25 The Trustees Of Columbia University In The City Of New York Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity
WO2005102374A2 (en) * 2004-03-03 2005-11-03 Diamyd Medical Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
CN101365494A (zh) * 2005-10-05 2009-02-11 贝希尔治疗学股份有限公司 治疗自身免疫性疾病的组合物和方法
EP2118309B1 (en) * 2006-12-29 2015-01-28 The Regents of the University of Colorado, a body corporate Diagnostic and therapeutic target for autoimmune diseases and uses thereof
US8354110B2 (en) * 2007-03-07 2013-01-15 Uti Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
US20090092637A1 (en) * 2007-04-24 2009-04-09 Diamyd Therapeutics Ab Medicaments and methods to treat autoimmune disease and cancer
CA2917512C (en) * 2007-10-12 2025-08-05 President And Fellows Of Harvard College VACCINE NANOTECHNOLOGY
US20110143994A1 (en) * 2007-12-19 2011-06-16 Nils Lycke Compositions and methods for treatment of autoimmune and allergic diseases
DK2621282T3 (da) * 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
WO2012062697A1 (en) * 2010-11-08 2012-05-18 Novartis Ag Combination therapy for type 1 diabetes
DE102011018499A1 (de) * 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes

Also Published As

Publication number Publication date
AU2020203169A1 (en) 2020-06-04
DK3151853T3 (da) 2020-07-27
CA2950893C (en) 2023-10-10
RU2702632C2 (ru) 2019-10-09
AU2015268960B2 (en) 2020-04-09
AU2020203169B2 (en) 2021-12-23
US20240299514A1 (en) 2024-09-12
JP2017516870A (ja) 2017-06-22
EP3760224A3 (en) 2021-03-31
RU2016150656A3 (enExample) 2019-01-25
LT3151853T (lt) 2020-08-10
RU2016150656A (ru) 2018-07-10
JP6686007B2 (ja) 2020-04-22
IL273265A (en) 2020-04-30
ES2807787T3 (es) 2021-02-24
IL249250A0 (en) 2017-02-28
RU2019129803A (ru) 2020-12-14
IL273265B2 (en) 2023-06-01
IL300130B2 (en) 2024-05-01
EP3151853A4 (en) 2018-04-25
WO2015187087A3 (en) 2016-01-28
IL300130A (en) 2023-03-01
EP3151853A2 (en) 2017-04-12
US20170196949A1 (en) 2017-07-13
ZA202204777B (en) 2024-09-25
HUE051151T2 (hu) 2021-03-01
PT3151853T (pt) 2020-07-27
CN114504639A (zh) 2022-05-17
EP3760224A2 (en) 2021-01-06
IL300130B1 (en) 2024-01-01
AU2022202003A1 (en) 2022-04-14
CN106535926A (zh) 2017-03-22
PL3151853T3 (pl) 2020-11-02
CA2950893A1 (en) 2015-12-10
AU2022202003B2 (en) 2024-12-12
IL249250B (en) 2020-03-31
SI3151853T1 (sl) 2020-10-30
EP3151853B1 (en) 2020-05-06
CY1123160T1 (el) 2021-10-29
CN106535926B (zh) 2022-02-01
JP2020125300A (ja) 2020-08-20
US20220000995A1 (en) 2022-01-06
AU2015268960A1 (en) 2016-12-15
WO2015187087A2 (en) 2015-12-10
CA3210184A1 (en) 2015-12-10
SMT202000384T1 (it) 2020-09-10

Similar Documents

Publication Publication Date Title
AU2022202003B2 (en) Novel combinations for antigen based therapy
Luo et al. Immunotherapy of type 1 diabetes: where are we and where should we be going?
Robert et al. Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice
Ludvigsson Therapies to preserve β-cell function in type 1 diabetes
CN101687019A (zh) 用于治疗自身免疫性疾病和癌症的药物和方法
Gupta Immunotherapies in diabetes mellitus type 1
Gallagher et al. Making progress: preserving beta cells in type 1 diabetes
JP2024041812A (ja) 改善された免疫療法
US20200138920A1 (en) Novel Combinations for Antigen Based Therapy
RU2824503C2 (ru) Новые комбинации для антигенной терапии
HK40043801A (en) Novel combinations for antigen based therapy
HK1232792B (en) Glutamic acid decarboxylase (gad) for use in the treatment of an autoimmune disease
HK1232792A1 (en) Glutamic acid decarboxylase (gad) for use in the treatment of an autoimmune disease
Orban et al. Prevention of type 1 diabetes mellitus using a novel vaccine
Ahmed A systematic review of the efficacy of gene therapy for diabetes and diabetes-related complications
Bloomgarden Type 1 diabetes and hypoglycemia
Sedimbi et al. Prevention of β-Cell Destruction in Autoimmune Diabetes: Current Approaches and Future Prospects
Osiris et al. More than insulin
Keil et al. Gastrointestinal Tract and Endocrine System
Mpofu-Mätzig et al. Gastrointestinal Tract and Endocrine System